Bristol Myers (BMY) boasts a strong oncology portfolio, featuring blockbuster drugs like Opdivo, Opdivo Qvantig, and Yervoy. Opdivo, with multiple oncology approvals, is a top revenue driver for the company, with sales of $2.5 billion in Q3 driven by label expansions and demand.

Opdivo Qvantig’s approval for subcutaneous use has further strengthened Bristol Myers’ oncology franchise, with sales reaching $67 million in Q3. Global sales of Opdivo, along with Qvantig, are expected to grow in the high single-digit to low double-digit range in 2025, driven by strong performance.

Despite label expansions, Bristol Myers faces competition in the immuno-oncology space from Merck’s Keytruda and Roche’s Tecentriq. Keytruda alone contributes over 50% of Merck’s pharmaceutical sales, while Roche’s Tecentriq is approved for various oncology indications.

Bristol Myers’ shares have declined by 12.9% year-to-date, trading at a discount to the large-cap pharma industry. The Zacks Consensus Estimate for 2025 EPS has increased, but decreased for 2026 EPS. Currently holding a Zacks Rank #3 (Hold), Bristol Myers continues to focus on label expansions and new drug approvals for revenue stabilization.

The convergence of artificial intelligence and quantum computing presents significant wealth-building opportunities. Investors can position their portfolios at the forefront of this technological revolution by exploring quantum computing stocks set to soar. Access the free report for insights on potential winners in the quantum computing race.

Read more at Nasdaq: Will Opdivo and Opdivo Qvantig Drive BMY’s Top-Line Growth?